Physician profile
Erin Everett
NPI 1891154613
$6,772.29
in general payments reported to CMS, 2019-2025
28 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 91% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $945 · 2022: $1,706 · 2023: $1,563 · 2024: $1,204 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,057 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,056.60 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,083.86 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $1,570.55 | 2021-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $506.65 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Lilly USA, LLC | $487.16 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $328.89 | 2021-2024 | |
| Theratechnologies INC. | $228.78 | 2021-2025 | Egrifta, Trogarzo, Egrifta Sv |
| Janssen Biotech, INC. | $224.36 | 2021-2023 | Symtuza |
| Emd Serono, INC. | $193.71 | 2023-2025 | Serostim |
| Novo Nordisk INC | $188.04 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $176.30 | 2021-2023 | Trintellix |
| Antares Pharma, INC. | $107.15 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Janssen Products, LP | $99.00 | 2022 | |
| Verity Pharmaceuticals INC. | $82.96 | 2024-2025 | Tlando |
| Janssen Scientific Affairs, LLC | $67.69 | 2021 | |
| Acerus Pharmaceuticals Corporation | $65.59 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $45.99 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $44.29 | 2021-2022 | |
| Tolmar, INC. | $37.98 | 2023 | |
| Clarus Therapeutics INC. | $35.63 | 2021 | |
| Halozyme INC | $34.34 | 2023 | |
| Dexcom, INC. | $32.27 | 2023-2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $24.39 | 2023 | Auvelity |
| Exact Sciences Corporation | $24.06 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $22.05 | 2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $19.17 | 2023 | Shingrix, Arexvy |
| Idorsia Pharmaceuticals US INC | $15.30 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $14.13 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Everett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.